Analyst Consensus ?
ConsensusBuy19 ratings
Bullish1157.9%
Neutral842.1%
Bearish00.0%
GE HealthCare Technologies Inc. · GEHC · FY2025 Q1 · Calendar Q2 2025
GE HealthCare: Strong Orders, Lower Guidance on Tariff Costs
The call supports a constructive operating picture through strong orders, backlog, U.S. imaging demand, and product launches, but the lowered guidance shows that tariff costs and execution risks currently temper the case for sustained earnings growth.
Reported Before market openNASDAQHealthcare
$29.69B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $0.91
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $4.66B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+3.3%
Event window
SPY move
+0.0%
Same window
Abnormal move
+3.3%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+1.7%
Up to 20 sessions
GEHCSPY benchmark
Ask FN2 about GEHC FY2025 Q1
Transcript, numbers and history already loaded
What drove GEHC's +3.3% move after FY2025 Q1 earnings?What changed in GEHC's guidance and outlook in FY2025 Q1?Give me the bull and bear case for GEHC after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the tone remained confident but the outlook became less supportive: tariff exposure led to lower adjusted EPS and free cash flow guidance. Management added tariff-mitigation actions, highlighted Flyrcado reimbursement and rollout progress, and reported continued order momentum.
Guidance delta
Guidance was lowered, with tariff exposure reducing adjusted EPS guidance by $0.85 per share and free cash flow guidance also reduced.
Key takeaways
- Management described double-digit order growth and 4% organic revenue growth, led by U.S. imaging demand.
- A record backlog and a 1.09 book-to-bill ratio support near-term revenue visibility.
- Tariffs lowered adjusted EPS guidance, while mitigation and supply-chain actions are intended to reduce exposure.
- Flyrcado rollout and the photon-counting CT pipeline remain important execution priorities.
Management priorities
- Expand Flyrcado across U.S. sites and increase contract-manufacturing capacity.
- Advance photon-counting CT toward FDA submission and a planned 2026 commercial launch.
- Use local-for-local sourcing, dual sourcing, targeted M&A, and the announced share-repurchase program to support execution.
Follow GEHC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$65.74Current
$65Low
$86.23Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 11, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Needham | Buy | Buy | Maintain | Oct 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Oct 5, 2026 |
| BTIG | Buy | Buy | Maintain | Sep 17, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 31, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 30, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Apr 30, 2026 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 30, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 30, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Apr 17, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Apr 13, 2026 |
| Stifel | Buy | Buy | Maintain | Feb 5, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Feb 5, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jan 5, 2026 |
| Jefferies | Buy | Buy | Maintain | Dec 11, 2025 |
| Argus Research | Buy | Buy | Maintain | Apr 1, 2024 |
| Oppenheimer | Outperform | Outperform | Maintain | May 16, 2023 |
| Redburn Partners | Buy | Buy | Maintain | Jan 19, 2023 |
| Edward Jones | Hold | Hold | Maintain | Jan 4, 2023 |
Named analyst price targets
Upside is calculated against the persisted current price $65.74. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $85 | $64.77 | +29.3% | Oct 6, 2026 |
| Needham | Analyst unavailable | $93 | $64.81 | +41.5% | Sep 22, 2026 |
| Evercore ISI | Analyst unavailable | $84 | $69.06 | +27.8% | Jul 30, 2026 |
| BTIG | Analyst unavailable | $79 | $71.54 | +20.2% | Jul 29, 2026 |
| UBS | Analyst unavailable | $67 | $64.23 | +1.9% | Jul 16, 2026 |
| BTIG | Ryan Zimmerman | $75 | $64.7 | +14.1% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $70 | $64.68 | +6.5% | Jul 8, 2026 |
| RBC Capital | Analyst unavailable | $80 | $60.64 | +21.7% | Jun 23, 2026 |
| UBS | Graham Doyle | $69 | $64.26 | +5.0% | May 21, 2026 |
| Evercore ISI | Analyst unavailable | $80 | $59.81 | +21.7% | Apr 30, 2026 |
| Oppenheimer | Suraj Kalia | $85 | $60.04 | +29.3% | Apr 30, 2026 |
| Barclays | Matt Miksic | $78 | $59.48 | +18.6% | Apr 30, 2026 |
| Goldman Sachs | David Roman | $65 | $59.48 | -1.1% | Apr 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $80 | $60.06 | +21.7% | Apr 29, 2026 |
| Piper Sandler | Analyst unavailable | $88 | $73.2 | +33.9% | Apr 17, 2026 |
| Mizuho Securities | Analyst unavailable | $90 | $72.69 | +36.9% | Apr 13, 2026 |
| Barclays | Analyst unavailable | $87 | $82.31 | +32.3% | Feb 6, 2026 |
| Stifel Nicolaus | Rick Wise | $98 | $82.63 | +49.1% | Feb 4, 2026 |
| Morgan Stanley | Analyst unavailable | $85 | $82.63 | +29.3% | Feb 4, 2026 |
| BTIG | Ryan Zimmerman | $91 | $83.7 | +38.4% | Feb 4, 2026 |
| Piper Sandler | Analyst unavailable | $94 | $78.78 | +43.0% | Jan 30, 2026 |
| UBS | Analyst unavailable | $77 | $85.3 | +17.1% | Jan 15, 2026 |
| Goldman Sachs | Analyst unavailable | $98 | $88.16 | +49.1% | Jan 9, 2026 |
| Stifel Nicolaus | Analyst unavailable | $95 | $86.73 | +44.5% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $95 | $84.2 | +44.5% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $105 | $85.54 | +59.7% | Dec 11, 2025 |
| Stifel Nicolaus | Rick Wise | $90 | $76.29 | +36.9% | Nov 21, 2025 |
| Wells Fargo | Larry Biegelsen | $87 | $77.38 | +32.3% | Oct 30, 2025 |
| BTIG | Analyst unavailable | $87 | $77.38 | +32.3% | Oct 29, 2025 |
| BTIG | Ryan Zimmerman | $89 | $71.01 | +35.4% | Oct 13, 2025 |
| Barclays | Analyst unavailable | $86 | $71.01 | +30.8% | Oct 13, 2025 |
| Morgan Stanley | Analyst unavailable | $74 | $74 | +12.6% | Sep 18, 2025 |
| UBS | Graham Doyle | $73 | $69.37 | +11.0% | May 5, 2025 |
| BTIG | Ryan Zimmerman | $95 | $64.39 | +44.5% | Apr 14, 2025 |
| Piper Sandler | Jason Bednar | $97 | $82.08 | +47.6% | Nov 15, 2024 |
| UBS | Graham Doyle | $74 | $93.01 | +12.6% | Sep 26, 2024 |
| Bank of America Securities | Craig Bijou | $97 | $90.62 | +47.6% | Sep 20, 2024 |
| BTIG | Ryan Zimmerman | $100 | $86.79 | +52.1% | Sep 18, 2024 |
| Goldman Sachs | David Roman | $87 | $78.45 | +32.3% | May 30, 2024 |
| Piper Sandler | Jason Bednar | $92 | $81.5 | +39.9% | May 21, 2024 |
| Mizuho Securities | Anthony Petrone | $105 | $77.74 | +59.7% | May 1, 2024 |
| Evercore ISI | Vijay Kumar | $96 | $76.24 | +46.0% | Apr 30, 2024 |
| Mizuho Securities | Anthony Petrone | $110 | $85.39 | +67.3% | Apr 11, 2024 |
| Argus Research | David Toung | $110 | $90.91 | +67.3% | Apr 1, 2024 |
| UBS | Graham Doyle | $88 | $83.17 | +33.9% | Feb 12, 2024 |
| Morgan Stanley | Patrick Wood | $76 | $77.17 | +15.6% | Jun 27, 2023 |
| Oppenheimer | Suraj Kalia | $97 | $77 | +47.6% | May 16, 2023 |
Track every rating change on GEHC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products.…
Historical context
All GEHC earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the GEHC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-23T03:38:32.114269+00:00
- Polygon adjusted daily market bars · 2026-10-11T21:40:44.924776+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-11T21:40:44.922578+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-11. For educational purposes only; not investment advice.